Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. Januar 2026 07:00 ET | Quelle: Protara Therapeutics

Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones

On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026 Received Breakthrough Therapy and Fast Track designations for...
07. Januar 2026 08:00 ET | Quelle: Protara Therapeutics

Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
07. Januar 2026 08:00 ET | Quelle: Protara Therapeutics

Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
05. Januar 2026 08:00 ET | Quelle: Protara Therapeutics

Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
08. Dezember 2025 16:05 ET | Quelle: Protara Therapeutics

Protara Announces Closing of $75 Million Public Offering

NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare...
04. Dezember 2025 22:03 ET | Quelle: Protara Therapeutics

Protara Announces Pricing of $75 Million Public Offering

NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare...
04. Dezember 2025 16:15 ET | Quelle: Protara Therapeutics

Protara Announces Proposed Public Offering

NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare...
03. Dezember 2025 08:00 ET | Quelle: Protara Therapeutics

Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients

TARA-002 demonstrates 72% complete response rate at any time in BCG-Naïve patientsTARA-002 demonstrates a 69% complete response rate at the 6-month landmark and a 50% complete response rate at the...
01. Dezember 2025 16:15 ET | Quelle: Protara Therapeutics

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
19. November 2025 08:00 ET | Quelle: Protara Therapeutics

Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

80% of patients that completed treatment and 100% of patients that completed the eight-week response assessment achieved clinical successClinical success achieved with one or two doses of TARA-002 in...

Nächste Seite